![CCO Neuroscience Podcast artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts125/v4/43/26/0b/43260b9c-7ab4-877f-ae3e-390a58ffe3b5/mza_11250881568325215311.jpg/100x100bb.jpg)
Assess the Efficacy and Safety of Emerging Strategies That Impact Brain Cholesterol Turnover
CCO Neuroscience Podcast
English - November 03, 2023 18:36 - 23 minutes - 21.2 MB - ★★★★★ - 3 ratingsCourses Education Science Life Sciences movement disorders neuromuscular disorders mood disorders Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Link to CME: Claim Credit - https://bit.ly/3OByCaE
In this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers:
How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settingsThe role of antiseizure medications in DEE treatment managementThe nonpharmacological treatment options available to patients with DEEsThe emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s diseaseResults from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequencyThe future of soticlestat as a treatment option for pediatric patients with DEEsPresenters:
Jonathan J. Halford, MD
Professor
Director, Translational Research Unit
Department of Neurology
Medical University of South Carolina
Charleston, SC
Cecil Hahn, MD, MPH, FRCPC
Professor
Pediatric Epileptologist
University of Toronto
Toronto, Ontario, Canada
Content based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Link to full program:
https://bit.ly/45UUpQy